A miR-20a/MAPK1/c-Myc regulatory feedback loop regulates breast carcinogenesis and chemoresistance

Cell Death and Differentiation

Volumn 25, Issue 2, 2018, Pages 406-420

  Si, Wengong ^a   Shen, Jiaying ^a   Du, Chengyong ^a   Chen, Danni ^a   Gu, Xidong ^b   Li, Chenggong ^a   Yao, Minya ^a   Pan, Jie ^a   Cheng, Junchi ^a   Jiang, Donghai ^a   Xu, Liang ^a   Bao, Chang ^a   Fu, Peifen ^a   Fan, Weimin ^a,c  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA 20A; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; ANTINEOPLASTIC AGENT; MAPK1 PROTEIN, HUMAN; MICRORNA; MIRN20 MICRORNA, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE 1;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; ENDOCYTOSIS; FEEDBACK SYSTEM; GENE EXPRESSION REGULATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TISSUE SPECIFICITY; BREAST TUMOR; CELL PROLIFERATION; DNA MICROARRAY; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; FEMALE; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MICRORNAS; MITOGEN-ACTIVATED PROTEIN KINASE 1; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTO-ONCOGENE PROTEINS C-MYC; TUMOR CELLS, CULTURED;

EID: 85045316983     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2017.176     Document Type: Article

References (54)

1. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016; 66: 115-132.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66: 7-30.
3. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 2013; 13: 714-726.
4. Park JW, Amarapurkar D, Chao Y, Chen PJ, Geschwind JF, Goh KL et al. Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC). Liver Int 2013; 33: 327-337.
5. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol 2005; 205: 275-292.
6. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008; 100: 672-679.
7. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-233.
8. Ambros V. The functions of animal microRNAs. Nature 2004; 431: 350-355.
9. Kim AH, Reimers M, Maher B, Williamson V, McMichael O, McClay JL et al. MicroRNA expression profiling in the prefrontal cortex of individuals affected with schizophrenia and bipolar disorders. Schizophr Res 2010; 124: 183-191.
10. Park EY, Chang E, Lee EJ, Lee HW, Kang HG, Chun KH et al. Targeting of miR34a-NOTCH1 axis reduced breast cancer stemness and chemoresistance. Cancer Res 2014; 74: 7573-7582.
11. Hu Q, Gong JP, Li J, Zhong SL, Chen WX, Zhang JY et al. Down-regulation of miRNA-452 is associated with adriamycin-resistance in breast cancer cells. Asian Pac J Cancer Prev 2014; 15: 5137-5142.
12. Li G, Wu X, Qian W, Cai H, Sun X, Zhang W et al. CCAR1 5' UTR as a natural miRancer of miR-1254 overrides tamoxifen resistance. Cell Res 2016; 26: 655-673.
13. Zhou M, Liu Z, Zhao Y, Ding Y, Liu H, Xi Y et al. MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem 2010; 285: 21496-21507.
14. Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 2007; 129: 1401-1414.
15. Foschini MP, Eusebi V. Rare (new) entities of the breast and medullary carcinoma. Pathology 2009; 41: 48-56.
16. Bertucci F, Finetti P, Cervera N, Charafe-Jauffret E, Mamessier E, Adélaïde J et al. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res 2006; 66: 4636-4644.
17. Vincent-Salomon A, Gruel N, Lucchesi C, Macgrogan G, Dendale R, Sigal-Zafrani B et al. Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res 2007; 9: R24.
18. Jiang D, Sui M, Zhong W, Huang Y, Fan W. Different administration strategies with paclitaxel induce distinct phenotypes of multidrug resistance in breast cancer cells. Cancer Lett 2013; 335: 404-411.
19. Mu W, Hu C, Zhang H, Qu Z, Cen J, Qiu Z et al. miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015; 25: 477-495.
20. Jiang D, Huang Y, Han N, Xu M, Xu L, Zhou L et al. Fulvestrant, a selective estrogen receptor down-regulator, sensitizes estrogen receptor negative breast tumors to chemotherapy. Cancer Lett 2014; 346: 292-299.
21. Zheng H, Liu Z, Liu T, Cai Y, Wang Y, Lin S et al. Fas signaling promotes chemoresistance in gastrointestinal cancer by up-regulating P-glycoprotein. Oncotarget 2014; 5: 10763-10777.
22. El Azreq MA, Naci D, Aoudjit F. Collagen/beta1 integrin signaling up-regulates the ABCC1/ MRP-1 transporter in an ERK/MAPK-dependent manner. Mol Biol Cell 2012; 23: 3473-3484.
23. Zhao BX, YB Sun, Wang SQ, Duan L, Huo QL, Ren F et al. Grape seed procyanidin reversal of p-glycoprotein associated multi-drug resistance via down-regulation of NF-kappaB and MAPK/ERK mediated YB-1 activity in A2780/T cells. Plos ONE 2013; 8: e71071.
24. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007; 1773: 1263-1284.
25. Lin JC, Chang SY, Hsieh DS, Lee CF, Yu DS. Modulation of mitogen-activated protein kinase cascades by differentiation-1 protein: acquired drug resistance of hormone independent prostate cancer cells. J Urol 2005; 174: 2022-2026.
26. Yan HL, Xue G, Mei Q, Wang YZ, Ding FX, Liu MF et al. Repression of the miR-17-92 cluster by p53 has an important function in hypoxia-induced apoptosis. EMBO J 2009; 28: 2719-2732.
27. Zhang L, Huang J, Yang N, Greshock J, Megraw MS, Giannakakis A et al. microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci USA 2006; 103: 9136-9141.
28. Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358: 1148-1159.
29. Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic PM, Blalock WL et al. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 2003; 17: 1263-1293.
30. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005; 435: 839-843.
31. Chang Y, Liu C, Yang J, Liu G, Feng F, Tang J et al. MiR-20a triggers metastasis of gallbladder carcinoma. J Hepatol 2013; 59: 518-527.
32. Wang M, Gu H, Qian H, Zhu W, Zhao C, Zhang X et al. miR-17-5p/20a are important markers for gastric cancer and murine double minute 2 participates in their functional regulation. Eur J Cancer 2013; 49: 2010-2021.
33. Huang G, Nishimoto K, Zhou Z, Hughes D, Kleinerman ES. miR-20a encoded by the miR-17-92 cluster increases the metastatic potential of osteosarcoma cells by regulating Fas expression. Cancer Res 2012; 72: 908-916.
34. Li X, Pan JH, Song B, Xiong EQ, Chen ZW, Zhou ZS et al. Suppression of CX43 expression by miR-20a in the progression of human prostate cancer. Cancer Biol Ther 2012; 13: 890-898.
35. Zhao S, Yao D, Chen J, Ding N, Ren F. MiR-20a promotes cervical cancer proliferation and metastasis in vitro and in vivo. PLoS ONE 2015; 10: e0120905.
36. Cheng D, Zhao S, Tang H, Zhang D, Sun H, Yu F et al. MicroRNA-20a-5p promotes colorectal cancer invasion and metastasis by downregulating Smad4. Oncotarget 2016; 7: 45199-45213.
37. Chang CC, Yang YJ, Li YJ, Chen ST, Lin BR, Wu TS et al. MicroRNA-17/20a functions to inhibit cell migration and can be used a prognostic marker in oral squamous cell carcinoma. Oral Oncol 2013; 49: 923-931.
38. Yan H, Wu J, Liu W, Zuo Y, Chen S, Zhang S et al. MicroRNA-20a overexpression inhibited proliferation and metastasis of pancreatic carcinoma cells. Hum Gene Therapy 2010; 21: 1723-1734.
39. Jing C, Ma G, Li X, Wu X, Huang F, Liu K et al. MicroRNA-17/20a impedes migration and invasion via TGF-beta/ITGB6 pathway in esophageal squamous cell carcinoma. Am J Cancer Res 2016; 6: 1549-1562.
40. Kim K, Chadalapaka G, Lee SO, Yamada D, Sastre-Garau X, Defossez PA et al. Identification of oncogenic microRNA-17-92/ZBTB4/specificity protein axis in breast cancer. Oncogene 2012; 31: 1034-1044.
41. Yu Z, Wang C, Wang M, Li Z, Casimiro MC, Liu M et al. A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. J Cell Biol 2008; 182: 509-517.
42. Yu Z, Willmarth NE, Zhou J, Katiyar S, Wang M, Liu Y et al. microRNA 17/20 inhibits cellular invasion and tumor metastasis in breast cancer by heterotypic signaling. Proc Natl Acad Sci USA 2010; 107: 8231-8236.
43. Chai H, Liu M, Tian R, Li X, Tang H. miR-20a targets BNIP2 and contributes chemotherapeutic resistance in colorectal adenocarcinoma SW480 and SW620 cell lines. Acta Biochim Biophys Sin (Shanghai) 2011; 43: 217-225.
44. Weng H, Huang H, Dong B, Zhao P, Zhou H, Qu L. Inhibition of miR-17 and miR-20a by oridonin triggers apoptosis and reverses chemoresistance by derepressing BIM-S. Cancer Res 2014; 74: 4409-4419.
45. Pu Y, Yi Q, Zhao F, Wang H, Cai W, Cai S. MiR-20a-5p represses multi-drug resistance in osteosarcoma by targeting the KIF26B gene. Cancer Cell Int 2016; 16: 64.
46. Jiang Z, Yin J, Fu W, Mo Y, Pan Y, Dai L et al. MiRNA 17 family regulates cisplatin-resistant and metastasis by targeting TGFbetaR2 in NSCLC. PLoS ONE 2014; 9: e94639.
47. Hou J, Lin L, Zhou W, Wang Z, Ding G, Dong Q et al. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell 2011; 19: 232-243.
48. Yu Z, Xu Z, Disante G, Wright J, Wang M, Li Y et al. miR-17/20 sensitization of breast cancer cells to chemotherapy-induced apoptosis requires Akt1. Oncotarget 2014; 5: 1083-1090.
49. Santarpia L, Lippman SM, El-Naggar AK. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets 2012; 16: 103-119.
50. Katayama K, Yoshioka S, Tsukahara S, Mitsuhashi J, Sugimoto Y. Inhibition of the mitogenactivated protein kinase pathway results in the down-regulation of P-glycoprotein. Mol Cancer Ther 2007; 6: 2092-2102.
51. Liao DJ, Dickson RB. c-Myc in breast cancer. Endocr Relat Cancer 2000; 7: 143-164.
52. Sears R, Leone G, DeGregori J, Nevins JR. Ras enhances Myc protein stability. Mol Cell 1999; 3: 169-179.
53. Ding S, Chamberlain M, McLaren A, Goh L, Duncan I, Wolf CR. Cross-talk between signalling pathways and the multidrug resistant protein MDR-1. Br J Cancer 2001; 85: 1175-1184.
54. Fang L, Li H, Wang L, Hu J, Jin T, Wang J et al. MicroRNA-17-5p promotes chemotherapeutic drug resistance and tumour metastasis of colorectal cancer by repressing PTEN expression. Oncotarget 2014; 5: 2974-2987.